Addition of navitoclax to ruxolitinib for myelofibrosis patients with relapsed/refractory disease and suboptimal response to ruxolitinib monotherapy: REFINE cohort 1 dose escalation and expansion
Pemmaraju, N Somervaille, TimCP Palandri, F Komrokji, RS Perkins, A Diaz, RMA Lavie, D Tomita, A Feng, Y Qin, Q
Pemmaraju, N
Somervaille, TimCP
Palandri, F
Komrokji, RS
Perkins, A
Diaz, RMA
Lavie, D
Tomita, A
Feng, Y
Qin, Q
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Pemmaraju N, Somervaille TCP, Palandri F, Komrokji RS, Perkins A, Diaz RMA, et al. Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023 SEP;23:S396-S7. PubMed PMID: WOS:001062479600379. English.